Fig. 3.

Changes in the urinary levels of NTx, a marker of bone turnover, associated with denosumab treatment were marked in the PO group. Up to week 78 of denosumab treatment, urinary NTx levels were statistically significantly lower in the PO group than in the RA and RA + GC groups. %NTx = $\frac{\text{NTx,value,for,each,week}-\text{NTx,value,at,the,start,of,treatment}}{\text{NTx,value,at,the,start,of,treatment}}\times 100$. Data are expressed as mean ± standard error. NTx type I collagen cross-linked N-telopeptide, PO patients with postmenopausal osteoporosis, RA osteoporosis patients with rheumatoid arthritis, RA + GC osteoporosis patients with rheumatoid arthritis taking glucocorticoids